| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Departments of*
Pathology, Molecular Biology and Genetics, Cell Biology, Pediatrics, and ¶ Gynecology and Obstetrics, Johns Hopkins University School of Medicine, Baltimore, MD 21205; and || Department of Host Defense, Research Institute for Microbial Diseases, Osaka University, Suita, Osaka, Japan
Vaccination with human papillomavirus type 16 (HPV16) L1 virus-like particles (VLP) induces both high titer neutralizing IgG and protective immunity. Because protection from experimental infection by papillomavirus is mediated by neutralizing IgG, we sought the mechanisms that trigger humoral immunity to HPV16 L1 VLP. We find that HPV16 L1 VLP bind to murine B lymphocytes thereby inducing activation-induced cytidine deaminase expression and Ig class switch recombination to cause the generation of IgG. HPV16 L1 VLP also activate production of proinflammatory factors IFN-
, IL-6, MIP-1, RANTES, and KC, up-regulate the expression of costimulatory molecules by naive B cells, and increase the B1 B cell subpopulation. These B cell responses to HPV16 L1 VLP are dependent upon MyD88. Although MyD88–/– B cells produce only µ transcript after exposure to HPV16 L1 VLP, MyD88+/+ B cells express , 
, and µ Ig H chain and activation-induced cytidine deaminase transcripts. Notably, TLR4 mutant C3H/HeJ mice exhibited significantly reduced HPV16 VLP-specific IgG1, IgG2a, IgG2b, and IgG3 titers after vaccination as compared with the control C3H/HeOuJ mice. HPV16 L1 VLP directly activated class switch recombination and costimulatory molecule expression by B cells of C3H/HeOuJ mice but not C3H/HeJ mice. Thus HPV16 L1 VLP directly activate B cells to induce CD4+ T cell independent humoral immune responses via TLR4- and MyD88-dependent signaling.
This article has been cited by other articles:
|
|
 |
|
  N. Thones, A. Herreiner, L. Schadlich, K. Piuko, and M. Muller A Direct Comparison of Human Papillomavirus Type 16 L1 Particles Reveals a Lower Immunogenicity of Capsomeres than Viruslike Particles with Respect to the Induced Antibody Response J. Virol., June 1, 2008; 82(11): 5472 - 5485. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Chackerian, M. R. Durfee, and J. T. Schiller Virus-Like Display of a Neo-Self Antigen Reverses B Cell Anergy in a B Cell Receptor Transgenic Mouse Model J. Immunol., May 1, 2008; 180(9): 5816 - 5825. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Woods, P. Soulas-Sprauel, B. Jaulhac, B. Arditi, A.-M. Knapp, J.-L. Pasquali, A.-S. Korganow, and T. Martin MyD88 Negatively Controls Hypergammaglobulinemia with Autoantibody Production during Bacterial Infection Infect. Immun., April 1, 2008; 76(4): 1657 - 1667. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Garcia-Pineres, A. Hildesheim, L. Dodd, T. J. Kemp, M. Williams, C. Harro, D. R. Lowy, J. T. Schiller, and L. A. Pinto Cytokine and Chemokine Profiles following Vaccination with Human Papillomavirus Type 16 L1 Virus-Like Particles Clin. Vaccine Immunol., August 1, 2007; 14(8): 984 - 989. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. M. Da Silva, S. C. Fausch, J. S. Verbeek, and W. M. Kast Uptake of Human Papillomavirus Virus-Like Particles by Dendritic Cells Is Mediated by Fc{gamma} Receptors and Contributes to Acquisition of T Cell Immunity J. Immunol., June 15, 2007; 178(12): 7587 - 7597. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. K. Huh, J. E. Kendrick, and R. D. Alvarez New Advances in Vaccine Technology and Improved Cervical Cancer Prevention Obstet. Gynecol., May 1, 2007; 109(5): 1187 - 1192. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. M. Guay, T. A. Andreyeva, R. L. Garcea, R. M. Welsh, and E. Szomolanyi-Tsuda MyD88 Is Required for the Formation of Long-Term Humoral Immunity to Virus Infection J. Immunol., April 15, 2007; 178(8): 5124 - 5131. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
U. A. Hasan, E. Bates, F. Takeshita, A. Biliato, R. Accardi, V. Bouvard, M. Mansour, I. Vincent, L. Gissmann, T. Iftner, et al. TLR9 Expression and Function Is Abolished by the Cervical Cancer-Associated Human Papillomavirus Type 16 J. Immunol., March 1, 2007; 178(5): 3186 - 3197. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. P. Ryan, C. M. Malboeuf, M. Bernard, R. C. Rose, and R. P. Phipps Cyclooxygenase-2 Inhibition Attenuates Antibody Responses against Human Papillomavirus-Like Particles J. Immunol., December 1, 2006; 177(11): 7811 - 7819. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
